Early detection of adverse events via prompt evaluation, cessation of IL-17 inhibitors, and initiation of alternative treatment (e.g., corticosteroids and anti-TNF therapy) can generally lead to clinical remission of IBD. The gene discussed is IL17A; the disease is inflammatory bowel disease.